MD&DI

11/20/2025

DEAL CONFIRMED: Abbott Acquires Exact Sciences for $21B 🎯

The rumors are now reality! Abbott Laboratories just announced its acquisition of Exact Sciences for $21 billion - potentially the biggest medtech deal of 2025.

The Numbers That Matter: 💰 $21B transaction value 📈 Exact Sciences shares jumped another 17% on confirmation 🚀 Combined diagnostics revenue will exceed $12B annually ⏰ Expected close: Q2 2026

Why This Changes Everything: Abbott's diagnostics division has been struggling post-COVID, with growth dropping to just 3-5% due to testing roll-offs and market pressures.

Exact Sciences brings immediate solutions:

✅ $3B+ revenue pipeline with high-teens growth rate
✅ Leading cancer screening portfolio (Cologuard, Oncotype DX, Cancerguard)
✅ Projected to add 2.5 percentage points of incremental growth
✅ Restores Abbott diagnostics to ~7% organic growth baseline

Strategic Brilliance: This isn't just about revenue - it's about Abbott's expansion into oncology diagnostics, leveraging their massive primary care network to scale Exact's innovative cancer screening technologies.

As Abbott CEO Robert Ford noted: "Abbott has repeatedly taken on the world's most challenging health issues... We're excited to bring Exact Sciences' people and know-how into Abbott so that together, we can take on the global challenge of cancer."

Market Context: This deal rivals Johnson & Johnson Abiomed acquisition (2022) and Siemens Healthineers' Varian deal (2021) in scale and strategic importance.

The medtech consolidation wave continues, and Abbott just made a massive statement about the future of cancer diagnostics.

What's your take on this mega-deal? Game-changer for cancer screening accessibility?

Abbott is moving to acquire Exact Sciences, a molecular diagnostics company that specializes in the detection of early-stage cancers, for $21 billion.

11/20/2025

Celebrate 100 years of VA medical breakthroughs and discover how to partner in driving the future of healthcare innovation with Gary Bloomer, VA Licensing Lead at TechLink. Dive in here: https://utm.io/ujnnS

Celebrate 100 years of VA medical breakthroughs and discover how to partner in driving the future of healthcare innovation.

11/19/2025

🎙️ Exciting insights from our latest Let's Talk Medtech episode!

Lishan Aklog, MD, shares compelling details about EsoGuard, a groundbreaking esophageal DNA test from Lucid Diagnostics that's changing the game in early detection.

This innovative test enables healthcare providers to detect Barrett's Esophagus and esophageal adenocarcinoma - potentially life-saving technology that could transform patient outcomes through earlier intervention.

The conversation highlights how cutting-edge diagnostic tools like EsoGuard are revolutionizing preventive care and giving patients better chances at successful treatment.

Don't miss this exclusive clip! And be sure to watch the full episode to learn more about the future of medtech innovation. https://youtu.be/gz799CgrmGU

11/12/2025

🏆 Celebrating Excellence in Medical Technology! 🏆

We're thrilled to announce the finalists for Medtech Company of the Year 2025! These industry leaders are driving innovation, advancing patient care, and shaping the future of healthcare technology.

2025 Finalists:
🔹 AngioDynamics
🔹 Boston Scientific
🔹 Carlsmed
🔹 FastWave Medical
🔹 Freudenberg Medical
🔹 Medtronic
🔹 Microbot Medical
🔹 Penumbra, Inc.
🔹 Stryker
🔹 Trinity Biotech

Each of these companies represents the pinnacle of medical device innovation, demonstrating exceptional commitment to improving patient outcomes through groundbreaking technologies and solutions.

From minimally invasive procedures to cutting-edge diagnostics, these finalists are transforming healthcare delivery and setting new standards for the industry.

Congratulations to all finalists! 👏

Which company's innovations have made the biggest impact on your work or patient care? Share your thoughts below!

These medical device and diagnostics companies have risen above the rest in 2025. Which one do you think deserves the title?

11/12/2025

When we first sat down with Lishan Aklog, MD Aklog in 2021, we barely scratched the surface of his fascinating transition into the medtech world.

Now, in our latest Let's Talk Medtech episode, the CEO of PAVmed Inc. and Lucid Diagnostics opens up about the pivotal moments that shaped his path.

His key insight? You need a healthy dose of audacity to truly transform healthcare.

Dr. Aklog's story isn't just about medical expertise – it's about having the courage to challenge conventions and push boundaries in an industry where lives hang in the balance.

Check out this exclusive clip where Dr. Aklog shares the mindset that every healthcare disruptor needs. Watch the full episode here: https://bit.ly/3LUWnvM

11/10/2025

In biopharmaceutical manufacturing, every wetted surface — from reactors to chromatography columns — plays a vital role in ensuring product purity, process reliability, and regulatory compliance. Selecting the right material is a key decision that impacts both performance and cost.

Manufacturers often face two options:
-High-performance alloys that offer superior durability and resistance.
-Common stainless steels that may require additional protective measures.

How does your organization approach material selection in critical applications?

Find out more from Patrick Dick, Technical Sales Representative at SilcoTek Corporation: https://utm.io/ujli6

Strategic materials for wetted surfaces can enhance product purity, equipment life, and regulatory compliance, and cost-effectively rival specialty alloys.

11/10/2025

Minimally invasive Microwave Ablation technology leader Baird Medical has launched in the Egyptian market, completing a procedure at Ain Shams Specialized Hospital in Cairo.

Dr. Amr Mahmoud performed a bone ablation on a 30-year-old male patient with thigh pain, using the Baird MWA system. Baird believes this shows the system’s usefulness in musculoskeletal applications, going beyond just soft tissue treatments.

Baird Medical launches in Egypt with the first bone ablation procedure using MWA system at Ain Shams Hospital.

11/10/2025

Discover how Pall Medical, now part of Cytiva, is setting new standards in contamination control for healthcare applications!

In this Show Short, Product Manager Jacques Hestres highlights Pall Medical's innovative filtration solutions, including:
· Micro IV filters designed for neonatal and pediatric care with low priming volume and effective air elimination.
· Customizable syringe filters with various connector options and pore sizes to meet diverse medical device needs.
· A comprehensive portfolio featuring sterile IV filters, bulk non-sterile filters, and proprietary Supor membranes for low-volume sensitive therapies.

Watch now to see how Pall Medical is revolutionizing patient safety in IV therapy and injections!

11/07/2025

Dexcom has issued a Class I recall for its G6 glucose sensor Android app due to a critical defect causing unexpected crashes. This issue could lead to missed glucose readings, alarms, and alerts—posing serious risks of hyperglycemic or hypoglycemic events.

To address the problem, Dexcom has retired older app versions, requiring users to update to version 1.15.0 immediately.

This recall follows other challenges Dexcom has faced this year, including user-reported issues with the G7 sensor and app malfunctions.

📲 Read the full story below.

Dexcom has issued a Class I recall for its G6 Android app due to crashes that could cause users to miss critical glucose alerts.

11/07/2025

As the medical device industry faces growing regulatory pressure and evolving sterilization challenges, ensuring biological safety and product sterility is more complex than ever.

In this Q&A, Nicole Cufaude and Dr. Egmont Semmler of TÜV SÜD offer insights into how manufacturers can future-proof their sterilization strategies, improve testing readiness, and navigate both novel and legacy sterilization pathways. https://utm.io/ujjRw

Learn the answers to 8 FAQs on novel sterilization pathways for medical device manufacturers — from testing to market — courtesy of TÜV SÜD America.

11/06/2025

Lisette Hilton's latest article in MD+DI reveals a critical shift in healthcare cybersecurity threats that every healthcare leader needs to understand. https://bit.ly/3LpG0Hw

Cybercriminals are pivoting from patient data theft to operational technology attacks.

Medical devices and hospital infrastructure are becoming prime targets, and traditional security measures aren't enough to protect against these sophisticated threats.

Why Asset Intelligence Matters: Asset intelligence provides comprehensive visibility into every connected device in your healthcare network - from MRI machines to infusion pumps. Without this visibility, you're essentially flying blind in an increasingly dangerous cyber landscape.

What cybersecurity measures is your organization implementing to protect critical medical devices?

Bad actors may be shifting from targeting patient records to attacking healthcare operational technology devices.

11/06/2025

Ritish Patnaik shares the fascinating origin story of Curve Biosciences' name in an exclusive interview clip with MD+DI.

The company, which recently secured $40 million in funding, is pioneering innovative blood testing technology for chronic disease monitoring.

Learn more about their groundbreaking work and recent funding milestone in the full article linked here: https://bit.ly/3JKTdds